Table 3 Selected ongoing immunotherapy-based clinical trials
Patient population | Regimen | Phase | NIH No |
|---|---|---|---|
HER2-negative advanced breast cancer | STEMVAC | I | NCT02157051 |
HER2-negative advanced breast cancer | WOKVAC | I | NCT02780401 |
HER2- negative metastatic breast cancer with BRCA1 or BRCA2 mutation | MEDI4736 with Olaparib | I/II | NCT02734004 |
HER2-negative metastatic breast cancer | MEDI4736 with Tremelimumab | II | NCT02536794 |
HER2-negative metastatic breast cancer | Pembrolizumab+Aromatase Inhibitor | II | NCT02648477 |
HER2-negative metastatic breast cancer | Pembrolizumab and Nab-paclitaxel | II | NCT02752685 |
Recurrent HER2-negative metastatic breast cancer | Opdivo & Abraxane | I | NCT02309177 |
Advanced triple negative breast cancer | Pembrolizumab plus chemotherapy | I/II | NCT02331251 |
Advanced triple negative breast cancer | AM0010 (recombinant human IL-10) | I | NCT02009449 |
Advanced triple negative breast cancer | MEDI4736 with Olaparib or Cediranib | I/II | NCT02484404 |
Advanced triple negative breast cancer | MEDI4736 with Vigil | II/III | NCT02725489 |
Advanced triple negative breast cancer | PVX-410 Vaccine in combination with Durvalumab | I | NCT02826434 |
Advanced triple negative breast cancer | Entinostat and Nivolumab with or without Ipilimumab | I | NCT02453620 |
Advanced triple negative breast cancer | Tremelimumab | II | NCT02527434 |
Advanced triple negative breast cancer | Atezolizumab+Nab-Paclitaxel | II | NCT02425891 |
Advanced triple negative breast cancer | PDR001 | I/II | NCT02404441 |
Metastatic triple-negative breast cancer | Pembrolizumab plus chemotherapy | I/II | NCT02734290 |
Metastatic triple-negative breast cancer | Halaven & Pembrolizumab | I/II | NCT02513472 |
Metastatic triple-negative breast cancer | Pembrolizumab with Carboplatin and Gemcitabine | II | NCT02755272 |
Metastatic triple-negative breast cancer | Pembrolizumab plus radiotherapy | II | NCT02730130 |
Metastatic triple-negative breast cancer | TAK-659 with Nivolumab | I | NCT02834247 |
Metastatic triple-negative breast cancer | CSF1R Inhibitor (PLX3397) with Pembrolizumab | I/II | NCT02452424 |
Metastatic triple-negative breast cancer | Single-dose Cyclophosphamide +Pembrolizumab | II | NCT02768701 |
Metastatic triple-negative breast cancer | Pembrolizumab | I | NCT02447003 |
Metastatic triple-negative breast cancer | Pembrolizumab | III | NCT02555657 |
Metastatic triple-negative breast cancer | Niraparib with Pembrolizumab | I/II | NCT02657889 |
Stage I-III triple negative breast cancer | MEDI4736 and chemotherapy before surgery | I/II | NCT02489448 |
HER2+ breast cancer | NeuVax with Herceptin | II | NCT01570036 |
HER2+ breast cancer | Atezolizumab with Trastuzumab Emtansine or with Trastuzumab and Pertuzumab | I | NCT02605915 |
HER2+ advanced breast cancer | AdHER2/neu dendritic cell vaccine | I | NCT01730118 |
ER+, stage I, II or III breast cancer | MONTANIDE™ ISA 51 VG combined with neoadjuvant chemotherapy | I/II | NCT02229084 |
Metastatic breast cancer | Hypofractionated radiotherapy with MEDI4736 and Tremelimumab | I | NCT02639026 |
Persistent Triple-Negative Disease | Personalized polyepitope DNA vaccine following neoadjuvant chemotherapy | I | NCT02348320 |